financetom
Business
financetom
/
Business
/
Thai EV output set to jump, sparking a price war in a bruised market
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Thai EV output set to jump, sparking a price war in a bruised market
Jan 30, 2025 11:19 PM

By Chayut Setboonsarng

BANGKOK - Thailand is bracing for an extended EV price war triggered by a surge in local production from Chinese car makers, a move likely to deal a further blow to a domestic auto industry already struggling with tumbling sales, industry experts said.

Electric vehicle sales in Thailand, Southeast Asia's largest EV market, are forecast to jump 40% this year, exceeding 100,000 units and reversing a 8% drop in sales last year, Suroj Sangsnit, president of Electric Vehicle Association of Thailand (EVAT), told Reuters.

The expected surge in sales is largely because of a national incentive programme that requires local production of 1.5 vehicles for each imported vehicle between 2022 and 2023 for companies to qualify for tax breaks - and to avoid paying hefty penalties.

The programme, which also includes price subsidies of up to 150,000 baht ($4,400), helped Southeast Asia's second-largest economy become the region's biggest EV market, which registered 70,000 new EVs last year. It imported about 84,000 EVs between 2022 and 2023.

But it now threatens to intensify bruising price competition in a weak market where auto sales are slumping because of tight credit conditions and ballooning household debt, analysts said.

Great Wall Motor for January, dropped the price of its Ora Good Cat as much as 270,000 baht, while GAC AION lopped 166,000 baht off the price tag of its AION Y Plus. Both are Chinese companies.

"Price wars will be prolonged, aggressive, and more widespread," said Siam Commercial Bank (SCB) Economic Intelligence Unit senior analyst Tita Phekanonth, adding that there also could be discounts for internal combustion engine vehicles.

Thailand, a major auto production hub in Asia, exports about three-fifths of locally manufactured vehicles.

The Board of Investment (BOI), which anchored the incentive programme, changed some of the rules in December - extending a battery production timeline and offering incentives for hybrids - to ease concerns of oversupply and a price war.

BOI chief Narit Therdsteerasukdi told Reuters that EV companies would start exporting this year as well, potentially easing oversupply.

"They are not restricted to right or left-hand drive either," he said, pointing out that Chinese carmakers were producing both EV variants in Thailand.

"Other markets like Indonesia have also seen investment from (China's) BYD and Neta," said Hathaiwal Tungkaterakul, a senior researcher at Kasikornbank, and those companies' EV exports compete with Thailand's.

Thai auto production dropped for the 17th consecutive month in December because of weak demand at home and abroad. Vehicle exports fell 8.8% in 2024, while domestic sales plunged 26%, the lowest in 15 years.

OVERSUPPLY CONCERN

Drawn by subsidies and tax incentives aimed at converting 30% of its annual auto production to EVs by 2030, Thailand, whose auto sector had long been dominated by Japanese firms, has seen a flurry of Chinese EV investment in recent years.

China's BYD, Great Wall Motor and others have poured more than 102.7 billion baht ($3 billion) into the country, according to EVAT.

BYD, Great Wall Motor, Changan and GAC AION, which launched their facilities in Thailand last year, did not respond to a Reuters request for comment on their strategies ahead of potential EV price cuts.

Carmakers failing to meet the local production requirements could face up to 400,000 baht ($11,806) per car in penalties and fees, said EVAT's Suroj, who is also the executive vice president of SAIC Motor-CP, a joint venture of China's SAIC Motor and Thailand's CP Group.

"It will be competitive," said Suroj, adding that locally produced vehicles will only qualify for subsidies if they are sold this year, after which government support will cease.

BYD has already come under government scrutiny for deep discounts of up to 340,000 baht per EV. The biggest EV seller in the country was cleared of wrongdoing by a consumer watchdog last year.

($1 = 33.6600 baht)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Fuji Soft Inc: Board Decided To Recommend Shareholders To Tender Shares To KKR-Backed Group's First Tender Offer
BRIEF-Fuji Soft Inc: Board Decided To Recommend Shareholders To Tender Shares To KKR-Backed Group's First Tender Offer
Sep 26, 2024
Sept 26 (Reuters) - Fuji Soft Inc: * FUJI SOFT INC - BOARD DECIDED TO RECOMMEND SHAREHOLDERS TO TENDER SHARES TO KKR-BACKED GROUP'S FIRST TENDER OFFER * FUJI SOFT INC - BOARD REMAINS UNDECIDED ABOUT WHETHER TO RECOMMEND KKR-BACKED GROUP'S SECOND TENDER OFFER Source text for Eikon: Further company coverage: ...
ING Comments on The Euro
ING Comments on The Euro
Sep 26, 2024
06:01 AM EDT, 09/26/2024 (MT Newswires) -- The support from China's stimulus story waned on Wednesday and EUR/USD's exploration above 1.1200 proved to be very short-lived amid quarter-end US dollar (USD) buying, said ING. Investors will likely see a bit more range-bound swings around the 1.110-1.120 area in the near term unless United States data offers clearer direction to markets,...
Evotec, Novo Nordisk Partner on Cell Therapies
Evotec, Novo Nordisk Partner on Cell Therapies
Sep 26, 2024
06:01 AM EDT, 09/26/2024 (MT Newswires) -- Evotec (EVO) and Novo Nordisk ( NVO ) said Thursday they are partnering to develop off-the-shelf cell therapies for possible commercialization. Financial terms of the deal were not disclosed. Under the agreement, Novo Nordisk ( NVO ) will provide funding for Evotec's research and development site in Gottingen, Germany, and its cell therapy...
Alnylam Pharma Confident in ATTR-CM Treatment's Market Potential, Cautious on Regulatory Risks, RBC Says
Alnylam Pharma Confident in ATTR-CM Treatment's Market Potential, Cautious on Regulatory Risks, RBC Says
Sep 26, 2024
03:43 PM EDT, 09/19/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) is very confident regarding a commercial uptake of its transthyretin amyloid cardiomyopathy, or ATTR-CM, treatment but remains cautious about regulatory challenges, RBC Capital Markets said in a Thursday note. On regulatory, language was a bit more guarded (mgmt did not definitively rule out the possibility of an AdCom)...
Copyright 2023-2026 - www.financetom.com All Rights Reserved